Your session is about to expire
What is Idhifa
Approved as Treatment by the FDA
Enasidenib, also called Idhifa, is approved by the FDA for 1 uses including Leukemia, Myelocytic, Acute .Effectiveness
When to interrupt dosage
The measure of Idhifa is contingent upon the diagnosed state. The dosage is also contingent upon the technique of administration listed in the following table.Warnings
There are 20 known major drug interactions with Idhifa.Idhifa Novel Uses: Which Conditions Have a Clinical Trial Featuring Idhifa?
71 active studies are investigating the effectiveness of Idhifa in ameliorating Acute Myelocytic Leukemia.Idhifa Reviews: What are patients saying about Idhifa?
Patient Q&A Section about idhifa
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Who manufactures IDHIFA?
"The FDA approved Idhifa for Celgene Corporation and the RealTime IDH2 Assay for Abbott Laboratories on August 1, 2017."
What is IDHIFA used for?
"IDHIFA is a medication that is used to treat people with acute myeloid leukemia who have an isocitrate. The safety and effectiveness of this medication has not been studied in children."
Is IDHIFA FDA-approved?
"is the date that the U.S. Food and Drug Administration approved enasidenib (IDHIFA, Celgene Corp.) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have an isocitrate dehydrogenase-2 (IDH2) mutation."
How is IDHIFA administered?
"The ideal dosage of IDHIFA is 100 mg taken by mouth once every day with or without food until the sicknessShow progression or intolerable poisonousness. For patients without sickness progression or intolerable poisonousness, treat for a base time of 6 months to allow time for clinical reaction."